

## CLINICAL SUMMARY

# Prevention of Ventilator-Associated Pneumonia (VAP) and Ventilator-Associated Conditions: A Randomized Controlled Trial with Subglottic Secretion Suctioning. Use of subglottic secretion drainage endotracheal tubes reduces incidence of VAP.

### AUTHORS

**Pierre Damas, MD, PhD<sup>1</sup>; Frédéric Frippiat, MD, PhD<sup>2</sup>; Arnaud Ancion, MD<sup>2</sup>; Jean-Luc Canivet, MD, PhD<sup>1</sup>; Bernard Lambermont, MD, PhD<sup>2</sup>; Nathalie Layios, MD<sup>1</sup>; Paul Massion, MD, PhD<sup>1</sup>; Philippe Morimont, MD, PhD<sup>2</sup>; Monique Nys, PhD<sup>1</sup>; Sonia Piret, MD<sup>1</sup>; Patrizio Lancellotti, MD, PhD<sup>2</sup>; Patricia Wiesen, MD<sup>1</sup>; Vincent D'orio, MD, PhD<sup>3</sup>; Nicolas Samalea<sup>1</sup>; Didier Ledoux, MD, PhD<sup>1</sup>**

<sup>1</sup>Department of General Intensive Care, University Hospital of Liege, Liège, Belgium.

<sup>2</sup>Department of Medicine, University Hospital of Liege, Liège, Belgium.

<sup>3</sup>Department of Emergency Medicine, University Hospital of Liege, Liège, Belgium.

### PUBLICATION OR PRESENTED

This work was performed at University Hospital of Liege, Liège, Belgium. The authors have disclosed that they do not have any potential conflicts of interest. For information regarding this article, E-mail: pdamas@chu.ulg.ac.be Copyright © 2014 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins DOI: 10.1097/CCM.0000000000000674

### AIM

The study aimed to determine the impact of subglottic secretion drainage on VAP rates. Additionally, it aimed to explore if this also had an impact on ventilator-associated conditions and antibiotic use.

### METHODOLOGY

This study was conducted in five ICUs in a single hospital. It was a randomized controlled trial where 352 intubated patients with a tube that allowed subglottic secretion suctioning were randomly assigned to either undergo subglottic suctioning (n = 170, group 1) or not (n = 182, group 2).

### RESULTS

Microbiologically confirmed ventilator-associated pneumonia (VAP) was detected with 15 patients in group 1 (8.8%) and 32 patients in group 2 (17.6%) (p = 0.018). Group 1 had a VAP rate of 9.6 per 1,000 ventilatory days while for group 2 it was 19.8 of 1,000 ventilatory days (p = 0.0076). Ventilator-associated conditions were observed in 21.8% and 22.5% in groups 1 and 2 respectively (p = 0.84). Of the 47 patients who developed VAP, 25 (58.2%) experienced a ventilator-associated condition. Lengths of ICU stay and mortality rates were similar between the groups; however, a ventilator-associated condition was associated with increased mortality. The total number of antibiotic days in group 1 was 1,696 of 2,754 ICU days (61.6%), and 1,965 of 2,868 ICU days in group 2 (68.5%) (p < 0.0001).

[Click here to view detailed product descriptions and prices.](#) **Call 800-397-5899 to order today!**

**Smiths Medical India Private Limited**  
508/509, Western Edge-2, W.E. Highway,  
Borivali ( E), Mumbai - 66, India  
Phone: +91 22 28705210  
Fax: +91 22 28705211  
[csindia@smiths-medical.com](mailto:csindia@smiths-medical.com)  
[www.smiths-medical.com](http://www.smiths-medical.com)

Find your local contact information at: [www.smiths-medical.com/customer-support/contact-us](http://www.smiths-medical.com/customer-support/contact-us)

MHYTCA-1226

smiths medical

Smiths Medical is part of the global technology business Smiths Group plc. Please see the Instructions for Use/Operator's Manual for a complete listing of the indications, contraindications, warnings, and precautions. The Smiths Medical design mark is a trademark of Smiths Medical. The symbol © indicates the trademark is registered in the U.S. Patent and Trademark Office and certain other countries. All other names and marks mentioned are the trademarks or service marks of their respective owners. ©2017 Smiths Medical. All rights reserved. GA194068EN-062017